fda compounding semaglutide enforcement 2025 news What Patients Need to Know About the GLP-1 Policy Changes September 2, 2025: U.S. compounding

GLP-1 Reduces appetite, slows gastric emptying GIP Enhances insulin, improves fat metabolism Glucagon Increases energy expenditure, burns fat Based on Phase 2 clinical trial data (published in NEJM, 2023), retatrutide's side effects are primarily gastrointestinal, similar to other GLP-1 agonists but with some differences due to the glucagon component

We are looking at not just your, uh, weight, but your body composition as well

Untested Formulas: Some pharmacies add other ingredients, like vitamin B12 , to their formulas

Equally important is the ability to track gameplay with well-designed dashboards and set limits proactively